Johnson & Johnson
introduced an eye-popping health care-product enterprise acquisition early Tuesday, having to pay $16.6 billion upfront for
Abiomed
which sells a tiny heart pump utilised to deal with critical cardiovascular ailments.
The deal will come as
Johnson & Johnson
(ticker: JNJ) prepares to spin off its purchaser-healthcare organization future year, and highlights the company’s new concentrate on its medtech division, which Johnson & Johnson aims to go into greater-growth segments of the market.
Johnson & Johnson
introduced an eye-popping health care-product enterprise acquisition early Tuesday, having to pay $16.6 billion upfront for
Abiomed
which sells a tiny heart pump utilised to deal with critical cardiovascular ailments.
The deal will come as
Johnson & Johnson
(ticker: JNJ) prepares to spin off its purchaser-healthcare organization future year, and highlights the company’s new concentrate on its medtech division, which Johnson & Johnson aims to go into greater-growth segments of the market.
